The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Contrave Extended-Release
naltrexone hydrochloride and bupropion hydrochloride · NALTREXONE HYDROCHLORIDE 8 mg/1; BUPROPION HYDROCHLORIDE 90 mg/1 · Tablet, Extended Release · Oral · Nalpropion Pharmaceuticals LLC
NDC 51267-0890-07 · 7 TABLET, EXTENDED RELEASE in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA200063
- TE code
- —
- Approval date
- Sep 10, 2014
- Patents / exclusivity
- 18 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 10828294 | Jul 2, 2034 |
| patent | 11998542 | Jul 2, 2034 |
| patent | 10231964 | Jul 2, 2034 |
| patent | 10835527 | Jul 2, 2034 |
| patent | 9633575 | Jun 25, 2033 |
| patent | 10403170 | Jun 5, 2033 |
| patent | 11139056 | Jun 5, 2033 |
| patent | 9248123 | Jan 13, 2032 |
| patent | 11033543 | Jan 10, 2031 |
| patent | 8916195 | Feb 2, 2030 |
| patent | 11324741 | May 29, 2029 |
| patent | 8088786 | Feb 3, 2029 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class III · TerminatedOct 5, 2018Orexigen Therapeutics, Inc. — Container packaging defect.
- Class III · TerminatedAug 9, 2018Orexigen Therapeutics, Inc. — Defective Container: Customer complaints of punctures in the bottle.
Manufacturers of naltrexone hydrochloride and bupropion hydrochloride (Tablet, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | NALTREXONE HYDROCHLORIDE 8 mg/1; BUPROPION HYDROCHLORIDE 90 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Nalpropion Pharmaceuticals LLC | NALTREXONE HYDROCHLORIDE 90 mg/1; BUPROPION HYDROCHLORIDE 8 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Nalpropion Pharmaceuticals LLC | BUPROPION HYDROCHLORIDE 90 mg/1; NALTREXONE HYDROCHLORIDE 8 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Contrave Extended-Release — NDC 51267-0890-07," retrieved September 3, 2026, https://drugdashboards.com/drug/51267089007.
Free to cite with attribution — see how the data is put together.